罗淞元,郑赫,吴樱,蔡安平,谭宁,冯颖青

• 1:广东省人民医院心内科广东省心血管病研究所广东省医学科学院南方医科大学广东省人民医院

摘要(Abstract)：

经导管去肾交感神经术（RDN）是一种通过导管微创介入手术使高血压患者降压的革新性手段，主要通过射频能量对分布于肾动脉及紧邻的交感神经进行消融，一定程度上阻断肾交感神经信号传导，从而降低交感神经兴奋性，并通过调节肾素-血管紧张素系统，进而实现一次手术长期平稳降压的效果。本文报道1例采用Symplicity Spyral肾动脉多极射频消融导管行RDN治疗35岁服用4种降压药血压仍然不理想的难治性高血压病患者，患者术后进行了6个月的随访，效果满意。

关键词(KeyWords)： 经导管去肾交感神经术;难治性高血压病

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 罗淞元,郑赫,吴樱,蔡安平,谭宁,冯颖青

参考文献(References)：

• [1] Webb AJ,Rothwell PM.Effect of dose and combination of antihypertensives on interindividual blood pressure variability:a systematic review[J].Stroke,2011,42(10):2860-2865.DOI:10.116 1/STROKEAHA.110.611566.
• [2]Webb A J,Fischer U.Mehta Z,et al.Effects of antihypertensivedrug class on interindividual variation in blood pressure and riskof stroke:a systematic review and Meta-analysis[J].Lancet,2010,375(9718):906-915.DOI:10.1016/S0140-6736(10)60235-8.
• [3] Krum H,Schlaich M,Whitbourn R,et al.Catheterbased renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J].Lancet,2009,373(9671):1275-1281.DOI:10.1016/S0140-6736(09)60566-3.
• [4] Esler MD,Krum H,Sobotka PA,et al.Renal sympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial):a randomised controlled trial[J].Lancet,2010,376(9756):1903-1909.DOI:10.1016/S0140-6736(10)62039-9.
• [5] Bhatt DL,Kandzari DE,O'Neill WW,et al.A controlled trial of renal denervation for resistant hypertension[J].N Engl J Med,2014,370(15):1393-1401.DOI:10.1056/NEJMoa1402670.
• [6]Bhatt DL,Vaduganathan M,Kandzari DE,et al.Long-term outcomes after catheter-based renal artery denervation for resistant hypertension:final follow-up of the randomised SYMPLICITY HTN-3 Trial[J].Lancet,2022,400(10361):1405-1416.DOI:10.1016/S0140-6736(22)01787-1.
• [7]Townsend RR,Mahfoud F,Kandzari DE,et al.Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(SPYRAL HTN-OFF MED):a randomised,sham-controlled,proof-of-concept trial[J].Lancet,2017,390(10108):2160-2170.DOI:10.1016/S0140-6736(17)32281-X.
• [8]B?hm M,Kario K,Kandzari DE,et al.Efficacy of catheterbased renal denervation in the absence of antihypertensive medications(SPYRAL HTN-OFF MED Pivotal):a multicentre,randomised,sham-controlled trial[J].Lancet,2020,395(10234):1444-1451.DOI:10.1016/S0140-6736(20)30554-7.
• [9] Kandzari DE,B?hm M,Mahfoud F,et al.Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J].Lancet,2018,391(10137):2346-2355.DOI:10.1016/S0140-6736(18)30951-6.
• [10]Mahfoud F,Kandzari DE,Kario K,et al.Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs(SPYRAL HTN-ON MED):a randomised,shamcontrolled trial[J].Lancet,2022,399(10333):1401-1410.DOI:10.1016/S0140-6736(22)00455-X.
• [11] Mahfoud F,Mancia G,Schmieder RE,et al.Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range[J].J Am Coll Cardiol,2022,80(20):1871-1880.DOI:10.1016/j.jacc.2022.08.802.
• [12] Barbato E,Azizi M,Schmieder RE,et al.Renal denervation in the management of hypertension in adults.A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J].Eur Heart J,2023,44(15):1313-1330.DOI:10.1093/eurheartj/ehad054.